Biopeople to Meet at BIO2013: Inside the World of Biotech’s Luminaries, Titans and Brainiacs
Partnering, networking and making new friends are all top-of-the-agenda for the biopharma industry’s largest U.S. gathering. As you’re preparing to join 16,500+ of your colleagues at the 2013 BIO International Convention in Chicago, we’d like to introduce you to a…
Cancer Research Through Time: Cure Should’ve Been Wrapped up by 1985
If you’re looking for a plenary speaker, pick a Pulitzer Prize winner. That was one of the corollary lessons to be had from the talk of Columbia University’s Siddhartha Mukherjee at the American Association for Cancer Research’s Annual Meeting on…
‘ImaginAb’ That! BioWorld Salutes ‘Overall Awesomeness’
We at BioWorld actually contemplated putting out a zany blog about biotech to commemorate April Fools’ Day – i.e. biotech firm develops drug for childhood cooties, or something equally ridiculous – but, in the end, we decided to pass. And…
Evolution: Survival of the Fittest, and Some Others
If you believe in evolution at all, you probably think of it as a good thing for the evolving organism, enabling it to keep up with its environment as that environment changes. I sure do. Of course, we realize that…
‘Indirect’ Fat Clogging NIH’s Arteries
In the days before the sequester tightened Washington’s belt, the National Institutes of Health (NIH) and several other federal agencies sent up warning shots of just what was at stake. Under the automatic budget cuts intended to put the national…
Statistical Tinkering in Device Regulation a Disservice to Patients
Despite the regulatory approval of new antiepileptic drugs (AED) over the past decade and the expansion of indications deemed suitable for epilepsy surgery, individuals with intractable seizures – roughly one in three epilepsy patients – still face a dearth of…
Omontys Recall Rings Alarm Over Biosimilars
Despite what the New York Times and its echoers have said, makers of innovative biologics have legitimate reason to sound alarms about automatic substitution of biosimilars that have not proven their interchangeability – and it’s not just because of the…
Patients Take the Lead in Clinical Whole Genome Sequencing
A decade after the first human genome sequence was completed, it would probably be fair to say that whole genome sequencing is not yet ready for prime time. The problem is not the technology ‑ it’s the resulting vast quantity…
‘Fast’ Progress: Ampligen Activist Ends Hunger Strike
Robert Miller, the patient advocating for Hemispherx Biopharma Inc.’s Ampligen (rintatolimod) for chronic fatigue syndrome by going on a hunger strike in protest of the FDA’s complete response letter, ended the hunger strike over the weekend. Progress was made, he said,…
On the ‘Gom-Boo,’ Ampligen, and Holding Out Hope
About a week ago, my obituary arrived by email. But something related, which you might think is weirder, happened Tuesday afternoon, and all of it involves chronic fatigue syndrome (CFS), and Hemispherx Biopharma Inc.’s drug candidate for it, Ampligen. More…
